The radioligand therapy (RLT) market growth continues to strengthen as health economics and outcomes research demonstrates the cost-effectiveness of radioligand therapy compared to alternative treatments for metastatic cancers, supporting reimbursement negotiations and market access across diverse healthcare systems. Economic evaluations of lutetium-177 PSMA-617 demonstrate quality-adjusted...